Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 59 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 1.6 to 1.
Financials
Financial year 2025
Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE from Gent, company number BE0821306819, closed financial year 2025 with a result of € 43,137 after tax. For that financial year Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE recorded a gross margin of € 222,860 and equity of € 1.8 million. Compared with financial year 2023, the result moved from € 260,238 to € 43,137. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 1.8 million
▼ 5% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 43,137
▼ 83% vs 2023
Profit after tax over the fiscal year.
€ 230,189
▼ 8% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 105,263 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1
▼ 0.2 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 48,540
▲ 7% vs 2023
€ 48,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 53,405
▼ 14% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 6,729
▼ 88% vs 2023
Loans from banks and other lenders, long and short.
€ 456,762
▲ 39% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 157,880
▲ 58% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2025 | Change 2023 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 723,051 | € 525,762 | € 530,858 | € 222,860 | ▼ 58% |
| Profit after taxes | € 391,200 | € 285,449 | € 260,238 | € 43,137 | ▼ 83% |
| Equity | € 1,734,285 | € 1,801,734 | € 1,851,972 | € 1,765,550 | ▼ 5% |
| Total debts | € 358,072 | € 573,630 | € 579,624 | € 621,371 | ▲ 7% |
| Cash | € 257,740 | € 239,680 | € 250,510 | € 230,189 | ▼ 8% |
| Land & buildings | € 123,272 | € 116,317 | € 109,362 | - | |
| Retained profit | € 1,715,685 | € 1,783,134 | € 1,833,372 | € 1,746,950 | ▼ 5% |
| Dividend | € 0 | € 218,000 | € 210,000 | € 105,263 | ▼ 50% |
| Bank debt | € 107,592 | € 78,484 | € 56,110 | € 6,729 | ▼ 88% |
| Balance sheet total | € 2,092,357 | € 2,375,364 | € 2,431,596 | € 2,386,921 | ▼ 2% |
| Employees (FTE) | 2.4 | 1.6 | 1.2 | 1 | ▼ 0.2 |
Key figures of Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE?
What happened at Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 43,137 (▼ 83% vs 2023). Source: NBB ↗
- Capital increase of € 252,000, published in the Gazette. Source: Staatsblad ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Gent. KBO
- Xavier Janssens became a director. NBB
In short
From € 391,200 profit in 2021 to € 43,137 profit in 2025.
Paid € 463,571 in corporate taxes since 2021.
Best year ever: 2021, with € 391,200 profit.
On average € 222,900 of value added per employee in 2025.
Management
Behind Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE is Xavier Janssens. Xavier Janssens is also behind SOCIETE ROYALE BELGE DE RHUMATOLOGIE KONINKLIJKE BELGISCHE VERENIGING VOOR REUMATOLOGIE.
Directors
According to the 2025 annual accounts
Xavier Janssens
Director
Also active at: SOCIETE ROYALE BELGE DE RHUMATOLOGIE KONINKLIJKE BELGISCHE VERENIGING VOOR REUMATOLOGIE
since 2009
Establishments
Establishment units
Physical locations of this company
Meersstraat 142
9000 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- JANSSENS Xavier Marie Claude Marcel Amand Emmanuel Etienne(oprichter) 100%
Details
- Company number
- 0821.306.819
- VAT number
- BE 0821.306.819
- Registered office
- Meersstraat 142, 9000 Gent
- Names & denominations
- Dr. JANSSENS REUMALEX-REUMATOLOGIE, VERZEKERINGSGENEESKUNDE EN MEDISCHE EXPERTISE
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 December 2009
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Activiteiten van huisartspraktijken
Activiteiten van medisch specialisten